Valuation: Bio-Techne Corporation

Capitalization 7B 6B 5.49B 5.2B 9.62B 670B 9.7B 65.48B 25.44B 318B 26.29B 25.73B 1,108B P/E ratio 2026 *
38.4x
P/E ratio 2027 * 32.3x
Enterprise value 6.93B 5.94B 5.43B 5.14B 9.52B 663B 9.6B 64.83B 25.18B 315B 26.02B 25.47B 1,097B EV / Sales 2026 *
5.73x
EV / Sales 2027 * 5.25x
Free-Float
99.7%
Yield 2026 *
0.72%
Yield 2027 * 0.72%
1 day-0.33%
1 week-12.12%
Current month-19.13%
1 month-23.73%
3 months-25.35%
6 months-24.65%
Current year-23.92%
1 week 44.12
Extreme 44.12
49.52
1 month 44.12
Extreme 44.12
62.47
Current year 44.12
Extreme 44.12
72.16
1 year 44.12
Extreme 44.12
72.16
3 years 44.12
Extreme 44.12
89.91
5 years 44.12
Extreme 44.12
135.96
10 years 23.92
Extreme 23.92
135.96
Manager TitleAgeSince
Chief Executive Officer 59 01/02/2024
Director of Finance/CFO 55 01/04/2014
Chief Tech/Sci/R&D Officer - 06/08/2023
Director TitleAgeSince
Chairman 70 02/11/2012
Director/Board Member 73 26/10/2017
Director/Board Member 56 19/05/2009
Change 5d. change 1-year change 3-years change Capi.($)
-0.33%-12.12%-6.52%-44.97% 7.03B
-0.82%-2.47%-16.89%-17.47% 42.33B
-3.77%-3.91%+38.50%+27.79% 35.19B
-0.31%+4.88%+278.60%+477.77% 31.88B
-0.99%-4.46%+20.35%-9.30% 28.77B
+2.41%-3.65%+31.50%+27.88% 26.78B
+0.78%-0.26% - - 15.13B
-1.50%-14.49%+198.14%+4,123.83% 13.51B
-2.47%-0.45%+132.15%+113.12% 12.82B
+0.99%-0.54%+8.67%-1.00% 12.12B
Average -0.60%-3.90%+76.05%+521.96% 22.56B
Weighted average by Cap. -0.76%-3.30%+73.09%+345.87%

Financials

2026 *2027 *
Net sales 1.21B 1.04B 947M 897M 1.66B 116B 1.67B 11.3B 4.39B 54.94B 4.54B 4.44B 191B 1.27B 1.09B 992M 940M 1.74B 121B 1.75B 11.84B 4.6B 57.56B 4.75B 4.65B 200B
Net income 184M 158M 144M 137M 253M 17.63B 255M 1.72B 670M 8.38B 692M 677M 29.16B 220M 189M 172M 163M 302M 21.04B 305M 2.06B 799M 10B 826M 808M 34.81B
Net Debt -70.15M -60.1M -54.95M -52.04M -96.34M -6.71B -97.12M -656M -255M -3.19B -263M -258M -11.09B -358M -307M -281M -266M -492M -34.25B -496M -3.35B -1.3B -16.27B -1.34B -1.32B -56.64B
Logo Bio-Techne Corporation
Bio-Techne Corporation specializes in the manufacture and marketing of products used in life science research. The group offers reagents and diagnostic tools for researchers, doctors, laboratories, pharmaceutical and biotechnology companies, etc. Net sales break down by family of products as follows: - biological and chemical reagents and analysis tools (71.3%): proteins, antibodies, molecules, culture serums, tools for cell work, tools for the study of proteins, immunoassay tools, etc.; - diagnostic and genomics products (28.4%): reagents and products used in blood analysis, nucleic acid analysis, tissue biopsy, gene analysis, cancer and genetic carrier screening, etc. ; - other (0.3%). Net sales are distributed geographically as follows: the United States (56%), the United Kingdom (4.5%), Europe/Middle East/Africa (21.8%), China (8.3%), Asia/Pacific (6.3%) and other (3.1%).
Employees
3,100
Date Price Change Volume
14/05/26 44.74 $ -0.33% 3,425,768
13/05/26 44.89 $ -5.34% 3,904,911
12/05/26 47.42 $ 0.00% 1,767,193
11/05/26 47.42 $ -1.94% 2,706,682
08/05/26 48.36 $ -5.01% 3,850,168
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
44.74USD
Average target price
62.64USD
Spread / Average Target
+40.00%

Quarterly revenue - Rate of surprise